Catalyst Pharmaceuticals Inc.

It earns by selling a small set of already-approved drugs, so income depends on continued prescribing rather than on new approvals landing in a given period. Income has stayed positive and revenue has grown across multiple consecutive years, and the cash generated from operations has consistently covered spending with room left over.

CompanyGraph reads its growth as coming in discrete steps: each new medicine is added to its portfolio by acquiring or licensing rights to a drug already developed elsewhere, and each new territory is added by handing marketing rights to a local partner rather than building its own operations there. Its returns on capital and assets sit toward the upper end of its industry peer group, a pattern consistent with a business that adds revenue without adding much underlying asset base.

Its own filings show it depends entirely on outside contract manufacturers for its products, since it holds no in-house production capacity: third-party manufacturers produce FIRDAPSE, Santhera supplies AGAMREE, and Eisai supplies FYCOMPA. It also depends on outside parties to run its clinical studies, on its licensing partners for continued drug supply, and on distributors and specialty pharmacies such as AnovoRx to reach patients; separately, CompanyGraph places it upstream of more industries than it depends on.

Its own filings name a small set of exclusive distributors and specialty pharmacies, including AnovoRx, that depend on it for product to dispense to patients, plus international partners such as KYE Pharmaceuticals in Canada and DyDo Pharma in Japan that depend on it for the rights to sell its drugs in their own territories. Wholesalers, specialty distributors, and the government and managed-care payers that reimburse for FYCOMPA also sit downstream of it; separately, CompanyGraph counts more industries as depending on what it supplies than industries it depends on.

CompanyGraph places it among a wide group of companies whose business depends in the same way on regulatory approval before a product earns money, so its underlying shape is common rather than rare within that comparison. Its own filings separately describe individual drugs as the only or first approved treatment of their kind for their conditions, but CompanyGraph cannot independently confirm how durable that position is or whether competitors could replicate it.

The company states that one of its medicines is the only approved treatment for its condition in its eligible patients, and that another is the first and only approved drug of its kind for its condition, meaning there is no alternative approved product for prescribers or patients to move to in those specific cases. This is the company's own description of its position; CompanyGraph has not seen an independent figure showing how much that shapes actual prescribing or patient retention.

The industry this company is grouped with is typically limited by whether a product can clear regulatory approval at all, an assumption CompanyGraph tests against this specific company rather than treats as given. Its own filings, describing products that are already approved, instead list unsuccessful commercialization, weak acceptance by physicians, patients or payors, and inadequate reimbursement as the risks it names first, alongside a small pool of eligible patients, which points more toward a limit on converting approved drugs into sustained, paid use than toward clearing new regulatory gates.

Its own filings point to concentration as a recurring exposure: Santhera and Eisai are each the sole named supplier for one of its licensed drugs, and its main products move through a single exclusive distributor before reaching patients, leaving few alternatives if any one link is disrupted. It also names competition, weak acceptance or reimbursement by payors, and a small eligible patient population among the risks it lists first, and separately discloses that control of the company has passed to Angelini Pharma, another pharmaceutical company.

Its own filings name the specific regulators that govern it: the FDA for drug approval and manufacturing, the DEA and state licensing bodies because one of its drugs is a controlled substance, and CMS, HHS and VA drug-pricing programs that shape what it is paid. Among the pressures it lists first are tariffs, competition, and whether physicians, patients and payors accept and reimburse its treatments, and it has separately been party to patent litigation over a competitor's attempt to sell a generic version of one of its drugs.